SNORA25: A Non-coding RNA Molecule Involved in Gene Expression and Protein Translation Regulation

Target Name: SNORA25

NCBI ID: G684959

SNORA25

Other Name(s): small nucleolar RNA, H/ACA box 25 | Small nucleolar RNA, H/ACA box 25 | SNORA25A | ACA25

SNORA25: A Non-coding RNA Molecule Involved in Gene Expression and Protein Translation Regulation

SNORA25, also known as small nucleolar RNA (snRNA), is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in various organisms, including humans. It is a part of the H/ACA box family of snRNAs, which are known for their ability to interact with the protein heat shock protein (HSP) HSP70. HSP70 is a well-known protein that is involved in the stress response and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The H/ACA box is a specific region of the HSP70 protein that is involved in the formation of the HSP70-snRNA complex.

SNORA25 is a 25-nt RNA molecule that is predominantly expressed in the nuclei of eukaryotic cells. It is highly stable and has a calculated melting temperature of 59.6掳C, which is within the range of melting temperatures for snRNAs. SNORA25 is capable of forming a stable complex with HSP70, which has been shown to enhance the stability of the SNORA25 molecule. This interaction between SNORA25 and HSP70 has important implications for the regulation of gene expression, as HSP70 has been shown to play a role in the stability and translation of various RNA molecules, including snRNAs.

One of the key functions of SNORA25 is its role in the regulation of gene expression. It has been shown to interact with various transcription factors, including the RNA polymerase II (RNA-II) complex. This interaction between SNORA25 and RNA-II allows for the regulation of gene expression at the post-transcriptional level, which includes the control of RNA stability, translation efficiency, and stability of mRNA. Additionally, SNORA25 has been shown to play a role in the regulation of microRNA (miRNA) expression, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

SNORA25 has also been shown to be involved in the regulation of protein translation. It has been shown to interact with the protein translation factor (PTF), which is a protein that is involved in the regulation of protein translation. This interaction between SNORA25 and PTF allows for the regulation of protein translation at the post-transcriptional level, which includes the control of protein stability and localization.

In addition to its role in gene expression and translation, SNORA25 has also been shown to have potential as a drug target or biomarker. Its stability and interaction with HSP70 have led to the hypothesis that SNORA25 may be a drug target for diseases associated with the dysfunction of HSP70, such as cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, its role in the regulation of gene expression and protein translation may also be a potential biomarker for these diseases.

In conclusion, SNORA25 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression and protein translation in various organisms, including humans. Its interaction with HSP70 and its potential as a drug target or biomarker make it an attractive target for further research. Further studies are needed to fully understand the mechanisms of SNORA25's role in post-transcriptional gene regulation and its potential as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, H/ACA Box 25

The "SNORA25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets